Adipose-derived stem cells and lattices
View Patent ↗The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides an adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.
1. An isolated population of stem cells, obtained from human adipose tissue having a CD marker profile comprising a combination of STRO-1+, CD29+, CD44+, CD71+, CD49D+, low or undetectable levels of CD 106, CD90+, and CD105+.
2. An isolated population of stem cells, obtained from human adipose tissue having a CD marker profile comprising
(a) STRO-1,
(b) CD49d,
(c) low or undetectable levels of CD106, and
(d) any one or more of CD29, CD44, CD71, CD90, SH3, and CD105, and
wherein the CD marker profile further comprises CD31−, and CD45−.
3. An isolated population of stem cells, obtained from human adipose tissue having a CD marker profile comprising a combination of STRO-1+, CD29+, CD44+, CD49D+, low or undetectable levels of CD106, CD71+, CD90+, CD105+, CD31−, and CD45−.